NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

NCT07261241 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

118

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma

Interventions

DRUG: Radiation: 131I-MIBG
DRUG: Dinutuximab
DRUG: Vorinostat

Sponsor

New Approaches to Neuroblastoma Therapy Consortium

Collaborators

[object Object]
[object Object]